FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966679991> ?p ?o ?g. }

• W1966679991 endingPage "89" @default.
• W1966679991 startingPage "81" @default.
• W1966679991 abstract "Aims Trastuzumab, in combination with chemotherapy, is the standard of care for patients with early and metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The Retreatment after HErceptin Adjuvant trial assessed the efficacy and safety of trastuzumab plus a taxane as first-line treatment for patients with metastatic breast cancer (MBC) who had relapsed after adjuvant trastuzumab for HER2-positive early breast cancer. Materials and methods In total, 43 patients with HER2-positive MBC who had received previous adjuvant trastuzumab for ≥10 months, with a relapse-free interval of ≥6 months after the last adjuvant trastuzumab dose, were recruited. Eligible patients (n = 41) were assigned to receive trastuzumab, either weekly or every 3 weeks, in combination with docetaxel or paclitaxel until disease progression. Results At the final analysis, with a median follow-up time of 40 months, a positive response was observed in 25/41 patients (61%; 95% confidence interval: 48.7–80.4%), stable disease in 7/41 (17.1%) and progressive disease in 6/41 (14.6%). Three patients had missing response assessments (one had no measurable lesions at baseline and two had no post-baseline tumour assessments). The median progression-free survival (PFS) was 8.0 months (95% confidence interval: 6–11 months) and the median overall survival was 25.0 months (16–33 months). No correlation was found between response rate, PFS or overall survival and the duration of adjuvant trastuzumab treatment, trastuzumab-free interval, relapse-free interval, hormone receptor status or type of pre-metastatic treatment. The most common adverse events (all grades) were alopecia (32%) and diarrhoea (32%). Six patients (14.6%) developed at least one serious adverse event. No congestive heart failure or any unexpected adverse events were reported. Conclusion Trastuzumab, in combination with a taxane, is an effective and well-tolerated first-line treatment for MBC in patients who relapse after trastuzumab-based adjuvant therapy." @default.
• W1966679991 created "2016-06-24" @default.
• W1966679991 creator A5004874011 @default.
• W1966679991 creator A5014284915 @default.
• W1966679991 creator A5021112555 @default.
• W1966679991 creator A5031698298 @default.
• W1966679991 creator A5039096447 @default.
• W1966679991 creator A5042046866 @default.
• W1966679991 creator A5068100907 @default.
• W1966679991 creator A5071613575 @default.
• W1966679991 creator A5079098518 @default.
• W1966679991 date "2014-02-01" @default.
• W1966679991 modified "2023-10-16" @default.
• W1966679991 title "Trastuzumab Retreatment after Relapse on Adjuvant Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Final Results of the Retreatment after Herceptin Adjuvant Trial" @default.
• W1966679991 cites W1914269090 @default.
• W1966679991 cites W1980601200 @default.
• W1966679991 cites W2018901205 @default.
• W1966679991 cites W2019607817 @default.
• W1966679991 cites W2034414538 @default.
• W1966679991 cites W2068449976 @default.
• W1966679991 cites W2078166106 @default.
• W1966679991 cites W2095156669 @default.
• W1966679991 cites W2098775844 @default.
• W1966679991 cites W2101299592 @default.
• W1966679991 cites W2101824720 @default.
• W1966679991 cites W2118191456 @default.
• W1966679991 cites W2119060677 @default.
• W1966679991 cites W2121915946 @default.
• W1966679991 cites W2125620887 @default.
• W1966679991 cites W2137591261 @default.
• W1966679991 cites W2141161352 @default.
• W1966679991 cites W2149773268 @default.
• W1966679991 cites W2152365295 @default.
• W1966679991 cites W2159459001 @default.
• W1966679991 cites W2159967578 @default.
• W1966679991 cites W2166199281 @default.
• W1966679991 cites W2318605753 @default.
• W1966679991 doi "https://doi.org/10.1016/j.clon.2013.08.011" @default.
• W1966679991 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24051172" @default.
• W1966679991 hasPublicationYear "2014" @default.
• W1966679991 type Work @default.
• W1966679991 sameAs 1966679991 @default.
• W1966679991 citedByCount "25" @default.
• W1966679991 countsByYear W19666799912014 @default.
• W1966679991 countsByYear W19666799912015 @default.
• W1966679991 countsByYear W19666799912016 @default.
• W1966679991 countsByYear W19666799912017 @default.
• W1966679991 countsByYear W19666799912018 @default.
• W1966679991 countsByYear W19666799912019 @default.
• W1966679991 countsByYear W19666799912020 @default.
• W1966679991 countsByYear W19666799912021 @default.
• W1966679991 countsByYear W19666799912022 @default.
• W1966679991 crossrefType "journal-article" @default.
• W1966679991 hasAuthorship W1966679991A5004874011 @default.
• W1966679991 hasAuthorship W1966679991A5014284915 @default.
• W1966679991 hasAuthorship W1966679991A5021112555 @default.
• W1966679991 hasAuthorship W1966679991A5031698298 @default.
• W1966679991 hasAuthorship W1966679991A5039096447 @default.
• W1966679991 hasAuthorship W1966679991A5042046866 @default.
• W1966679991 hasAuthorship W1966679991A5068100907 @default.
• W1966679991 hasAuthorship W1966679991A5071613575 @default.
• W1966679991 hasAuthorship W1966679991A5079098518 @default.
• W1966679991 hasConcept C121608353 @default.
• W1966679991 hasConcept C126322002 @default.
• W1966679991 hasConcept C143998085 @default.
• W1966679991 hasConcept C2775930923 @default.
• W1966679991 hasConcept C2777511904 @default.
• W1966679991 hasConcept C2777863537 @default.
• W1966679991 hasConcept C2777982462 @default.
• W1966679991 hasConcept C2779786085 @default.
• W1966679991 hasConcept C2781190966 @default.
• W1966679991 hasConcept C530470458 @default.
• W1966679991 hasConcept C71924100 @default.
• W1966679991 hasConceptScore W1966679991C121608353 @default.
• W1966679991 hasConceptScore W1966679991C126322002 @default.
• W1966679991 hasConceptScore W1966679991C143998085 @default.
• W1966679991 hasConceptScore W1966679991C2775930923 @default.
• W1966679991 hasConceptScore W1966679991C2777511904 @default.
• W1966679991 hasConceptScore W1966679991C2777863537 @default.
• W1966679991 hasConceptScore W1966679991C2777982462 @default.
• W1966679991 hasConceptScore W1966679991C2779786085 @default.
• W1966679991 hasConceptScore W1966679991C2781190966 @default.
• W1966679991 hasConceptScore W1966679991C530470458 @default.
• W1966679991 hasConceptScore W1966679991C71924100 @default.
• W1966679991 hasIssue "2" @default.
• W1966679991 hasLocation W19666799911 @default.
• W1966679991 hasLocation W19666799912 @default.
• W1966679991 hasOpenAccess W1966679991 @default.
• W1966679991 hasPrimaryLocation W19666799911 @default.
• W1966679991 hasRelatedWork W1971716849 @default.
• W1966679991 hasRelatedWork W2014205823 @default.
• W1966679991 hasRelatedWork W2050605839 @default.
• W1966679991 hasRelatedWork W2163622510 @default.
• W1966679991 hasRelatedWork W2284635121 @default.
• W1966679991 hasRelatedWork W2394860297 @default.
• W1966679991 hasRelatedWork W2415167417 @default.
• W1966679991 hasRelatedWork W3010153683 @default.
• W1966679991 hasRelatedWork W3173641743 @default.

• next